Haemacure completes trial of Hemaseel:
This article was originally published in Clinica
Executive Summary
Haemacure's Hemaseel has shown no significant side-effects in a Phase I human trial. The study investigated the safety of a single dose of the fibrin sealant applied topically to a small incision on the forearm of ten volunteers. Haemacure, which is based in Montreal, Canada, conducted the study of its sealant intended to control bleeding in orthopaedic and general surgery at the Chelsea and Westminster Hospital in London, UK.